Literature DB >> 21506014

Cell Fusion, Drug Resistance and Recurrence CSCs.

Christa Nagler1, Kurt S Zänker, Thomas Dittmar.   

Abstract

Cancer stem cells (CSCs) are a rare population of cancer cells exhibiting stem cell properties, such as self-renewal, differentiation and tissue restoration. Beside the initiation of the primary tumor, CSCs have also been associated with metastasis formation and cancer relapses. In the context of cancer relapses, we have recently postulated the existence of so-called recurrence CSCs (rCSCs). These specific CSC subtype will initiate relapses exhibiting an "oncogenic resistance" phenotype, which are characterized by a markedly increased malignancy concomitant with a drug resistance towards first line therapy. In the present chapter we will discuss the necessity of rCSCs as a distinct CSC subtype and that cell fusion could be one mechanism how rCSCs could originate.

Entities:  

Mesh:

Year:  2011        PMID: 21506014     DOI: 10.1007/978-94-007-0782-5_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  19 in total

1.  Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.

Authors:  Tameka A Bailey; Haitao Luan; Robert J Clubb; Mayumi Naramura; Vimla Band; Srikumar M Raja; Hamid Band
Journal:  J Carcinog       Date:  2011-11-30

2.  Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk.

Authors:  Cem Ozel; Jeanette Seidel; Sönke Meyer-Staeckling; Burkhard H Brandt; Bernd Niggemann; Kurt S Zänker; Thomas Dittmar
Journal:  Cell Commun Signal       Date:  2012-04-09       Impact factor: 5.712

Review 3.  The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Authors:  Marisa Rosso; Miguel Muñoz; Michael Berger
Journal:  ScientificWorldJournal       Date:  2012-04-01

4.  Safety and Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells Therapy for Retinal Degeneration.

Authors:  S N Leow; Chi D Luu; M H Hairul Nizam; P L Mok; R Ruhaslizan; H S Wong; Wan Haslina Wan Abdul Halim; M H Ng; B H I Ruszymah; S R Chowdhury; M L C Bastion; K Y Then
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

5.  IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.

Authors:  Azucena Gomez-Cabrero; Wolfgang Wrasidlo; Ralph A Reisfeld
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.

Authors:  Y Zhu; H Liu; L Xu; H An; W Liu; Y Liu; Z Lin; J Xu
Journal:  Cell Death Dis       Date:  2015-02-12       Impact factor: 8.469

7.  Advantages of a dual-color fluorescence-tracing glioma orthotopic implantation model: Detecting tumor location, angiogenesis, cellular fusion and the tumor microenvironment.

Authors:  Yuntian Shen; Quanbin Zhang; Jinshi Zhang; Zhaohui Lu; Aidong Wang; Xifeng Fei; Xingliang Dai; Jinding Wu; Zhimin Wang; Yaodong Zhao; Y E Tian; Jun Dong; Qing Lan; Qiang Huang
Journal:  Exp Ther Med       Date:  2015-10-22       Impact factor: 2.447

8.  Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer.

Authors:  Viviana Castillo; Rodrigo Valenzuela; Christian Huidobro; Hector R Contreras; Enrique A Castellon
Journal:  Int J Oncol       Date:  2014-06-27       Impact factor: 5.650

9.  STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.

Authors:  Lin-Lin Bu; Zhi-Li Zhao; Jian-Feng Liu; Si-Rui Ma; Cong-Fa Huang; Bing Liu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncotarget       Date:  2015-12-08

10.  Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness.

Authors:  Jianguo Xue; Yuan Zhu; Zixuan Sun; Runbi Ji; Xu Zhang; Wenrong Xu; Xiao Yuan; Bin Zhang; Yongmin Yan; Lei Yin; Huijuan Xu; Leilei Zhang; Wei Zhu; Hui Qian
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.